Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139845 | 0.88 | CYP3A4 (0.59) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL5869239 | 0.88 | GRM2 (0.52) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL5557822 | 0.83 | GRM2 (0.69) | CYP3A4GRM2 | |
| SCHEMBL5563757 | 0.83 | CYP3A4 (0.60) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL5557011 | 0.83 | CYP3A4 (0.65) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL5562774 | 0.83 | CYP3A4 (0.59) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL6166237 | 0.83 | GRM2 (0.47) | CYP3A4RAB9ASMN1; SMN2GRM2 | |
| SCHEMBL6164369 | 0.81 | GRM2 (0.50) | CYP3A4GRM2 | |
| SCHEMBL5563880 | 0.81 | CYP3A4 (0.69) | CYP3A4GRM2 | |
| SCHEMBL2319292 | 0.81 | CYP3A4 (0.66) | CYP3A4RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | claimed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | claimed |
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | CYP3A4 3296/4885RAB9A 1527/4885SMN1; SMN2 4427/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | CYP3A4 2838/4885RAB9A 2325/4885SMN1; SMN2 4608/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | CYP3A4 2838/4885RAB9A 2325/4885SMN1; SMN2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.